Previous close | 6.06 |
Open | 5.99 |
Bid | 4.95 x 100 |
Ask | 5.17 x 100 |
Day's range | 4.95 - 6.08 |
52-week range | 0.61 - 9.37 |
Volume | |
Avg. volume | 1,094,167 |
Market cap | 108.186M |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.31 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.00 |
In this piece, we will take a look at the 12 most profitable biotech stocks to invest in. If you want to skip our overview of the global biotechnology industry and the latest trends, then you can take a look at the 5 Most Profitable Biotech Stocks To Invest In. Biotechnology is the riskiest and […]
Management to host virtual investor event on April 8 to highlight preliminary Phase 1 Data for VIP236, our first-in-class small molecule-drug conjugate (SMDC)PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting
Key Insights Given the large stake in the stock by institutions, Vincerx Pharma's stock price might be vulnerable to...